WebDoctor Encyclopedia

Article

Total Body Irradiation (TBI)

What is total body irradiation?

Total body irradiation (TBI) is a type of radiotherapy given to the whole body, rather than to one part of it. It is used almost entirely as part of the preparation, called conditioning, before an allogeneic stem cell transplant, in which a person receives blood-forming stem cells from a donor.

TBI has three jobs. It kills leukaemia cells anywhere in the body, including places that chemotherapy reaches poorly, such as the brain and the testes. It weakens the immune system so that the donor cells are not rejected. And at higher doses it clears space in the bone marrow for the new stem cells to grow.

TBI is given together with chemotherapy, usually over a few days just before the transplant. It is not used on its own to treat cancer. There are two broad approaches: high-dose (myeloablative) TBI, which wipes out the bone marrow, and low-dose TBI, which mainly suppresses the immune system and is gentler.

A brief history

Studies in the 1950s showed that animals given lethal doses of radiation could be rescued by an infusion of bone marrow. In the 1960s and 1970s, E. Donnall Thomas and his team in Seattle combined TBI with chemotherapy and marrow from matched donors to treat people with leukaemia, work that earned him the Nobel Prize in 1990.

Fractionation (splitting the dose into smaller treatments) and shielding of the lungs later made TBI safer. In the 2000s, very low-dose TBI made transplant possible for older and less fit people.

1. Key facts at a glance

Feature Details
Type of treatment External beam radiotherapy to the whole body
Main use Conditioning before allogeneic stem cell transplant
Common conditions Acute lymphoblastic leukaemia, acute myeloid leukaemia, myelodysplastic syndromes
High dose Often 12 Gy split into 6 treatments over 3 days
Low dose Often 2 Gy as a single treatment
Combined with Chemotherapy such as cyclophosphamide, etoposide or fludarabine
Main side effects Nausea, tiredness, mouth soreness, low blood counts; later cataracts, infertility, hormone and growth problems

2. How it works

Radiation and leukaemia cells

Radiation damages the DNA of cells. Blood cells, leukaemia cells and immune cells are among the most sensitive cells in the body, so even a modest dose kills many of them. Because the whole body is treated, cancer cells hiding in places that drugs reach poorly are also exposed.

Myeloablative and low-dose TBI

Approach Typical dose Purpose
High-dose (myeloablative) TBI About 12-14 Gy in several fractions Destroys bone marrow and leukaemia cells; requires a transplant to recover
Low-dose (non-myeloablative) TBI About 2-4 Gy Mainly suppresses the immune system to allow donor cells to take hold

In low-dose regimens, much of the anti-cancer effect comes from the donor immune cells, which recognise and attack the leukaemia. This is called the graft-versus-leukaemia effect.

Protecting the lungs and other organs

The lungs are the main organs at risk from high-dose TBI. Shielding blocks or adjustments to the radiation beam are used to keep the lung dose lower. Some centres now use newer techniques that shape the dose so that the bone marrow and lymph nodes get more radiation while organs receive less. These are called total marrow irradiation or total marrow and lymphoid irradiation.

3. Who it is for

Conditions treated

Condition Role of TBI
Acute lymphoblastic leukaemia Standard part of conditioning for many children and adults
Acute myeloid leukaemia One conditioning option; low-dose TBI in older people
Myelodysplastic syndromes Low-dose or high-dose regimens before transplant
Mixed phenotype acute leukaemia Often treated with transplant using TBI-based conditioning
Chronic myeloid leukaemia Occasionally, when transplant is needed
Juvenile myelomonocytic leukaemia Rarely; chemotherapy-only conditioning is usually preferred

Who may receive high-dose TBI

High-dose TBI is usually reserved for younger, fitter people, particularly those with acute lymphoblastic leukaemia. In very young children, chemotherapy-only conditioning is often preferred because radiation can affect growth and brain development.

Who may receive low-dose TBI

Low-dose TBI is often used for older people or those with other health problems who could not safely receive high-dose conditioning. In an early trial of 45 patients with a median age of 56, a 2 Gy dose followed by immune-suppressing drugs was gentle enough that about half of eligible patients had their transplant entirely as outpatients (McSweeney et al., 2001).

4. Before treatment

Step Why it is done
Transplant assessment Confirms that transplant is the right treatment
Donor match A suitable donor is found
Heart, lung and kidney tests Check fitness for conditioning
Radiotherapy planning visit Measurements and sometimes a CT scan
Fertility discussion High-dose TBI almost always causes infertility
Dental check Reduces the risk of mouth infection
Central line A long-term line is placed for treatment and blood tests

Fertility

High-dose TBI usually causes permanent infertility. Before treatment, adults and older children may be offered sperm or egg freezing, and sometimes freezing of ovarian or testicular tissue. This should be discussed early, because there is often little time between diagnosis and transplant.

5. What to expect: step by step

Step What happens
1. Admission To the transplant unit, usually a few days before treatment
2. Chemotherapy Given before or after TBI, depending on the regimen
3. Positioning You lie or stand in a set position, sometimes with a support frame
4. Radiation Delivered from a distance so the whole body is covered
5. Shielding Blocks may protect the lungs during part of each treatment
6. Repeat High-dose TBI is usually given twice a day for 3-4 days
7. Transplant Donor stem cells are given through a drip after conditioning

During each session

Each TBI treatment takes longer than standard radiotherapy, often 20-40 minutes, because the dose rate is kept low. You need to stay still, but you can usually talk with the team through an intercom and listen to music. The radiation itself is painless.

Coping during the treatment days

The days of conditioning can be tiring. Many people find it helps to bring something familiar into the treatment room, such as a playlist or an audiobook. Children are often supported by play specialists, who explain each step with pictures or toys and help them practise lying still. Anti-sickness medicines work best when taken on schedule rather than waiting for nausea to start, so let the team know early if they are not working.

Sucking ice chips or using mouth rinses as advised can ease the swollen, dry feeling in the mouth and jaw. Drink regularly unless you are told otherwise, and keep a note of any new symptoms so that you can mention them at the daily ward round.

6. Side effects and risks

Early side effects

Side effect What to expect
Nausea and vomiting Common; anti-sickness medicines are given beforehand
Tiredness Common
Swollen salivary glands Tender swelling near the jaw in the first day or two
Diarrhoea Common
Sore mouth (mucositis) Peaks 1-2 weeks after transplant
Hair loss Temporary
Low blood counts Expected after high-dose conditioning until the donor cells grow
Skin redness Mild

Late effects

Late effect Notes
Infertility Very common after high-dose TBI
Cataracts Can develop years later; treatable with surgery
Hormone problems Including an underactive thyroid and early menopause
Growth problems in children Reduced height and bone growth
Lung problems Inflammation or scarring
Second cancers Small increased risk over many years
Learning effects in young children More likely when TBI is given at a very young age

Weighing benefits and late effects

Late effects are the main reason researchers have tried to replace TBI with chemotherapy alone. A review of trials comparing TBI with cyclophosphamide against busulfan and cyclophosphamide found lower treatment-related deaths with the TBI regimen, but TBI-based conditioning caused more growth and development problems in children (Gupta et al., 2011).

7. Results and outlook

Study Main finding
FORUM trial, children and young people with ALL Two-year survival was 91% after TBI with etoposide versus 75% after chemotherapy-only conditioning; relapse was 12% versus 33% (Peters et al., 2021)
Systematic review of leukaemia conditioning TBI with cyclophosphamide had fewer transplant-related deaths than busulfan with cyclophosphamide, without a clear survival difference (Gupta et al., 2011)
Low-dose TBI in older patients Showed that a 2 Gy regimen allowed donor cells to engraft with mild toxicity (McSweeney et al., 2001)

What the FORUM trial changed

The FORUM trial was designed to see whether chemotherapy could replace TBI for children over 4 with high-risk ALL. The trial stopped early because the chemotherapy-only group did clearly worse. As a result, TBI with etoposide remains the recommended conditioning for this group (Peters et al., 2021).

Standards for delivery

Techniques for TBI vary between centres in dose, dose rate and set-up. International guidelines describe how to plan and deliver it safely, including how to measure the dose and protect the lungs (Wong et al., 2018).

8. Recovery and aftercare

In hospital

After the transplant, you stay in hospital until the donor cells have started making new blood cells, usually 2-4 weeks. During this time you have blood transfusions, antibiotics and close monitoring for infection and graft-versus-host disease.

At home

Tip Why
Follow infection precautions Your immune system takes months to recover
Protect your skin from sun Skin is more sensitive
Eat a balanced diet Supports recovery
Stay active gently Helps fatigue
Keep all follow-up appointments Detect complications early

Long-term follow-up

Check Why
Eye examinations Look for cataracts
Thyroid and hormone tests Detect underactive thyroid and other hormone changes
Growth monitoring in children Height, puberty and bone health
Lung function tests Detect lung damage
Skin and cancer screening Due to second cancer risk
Bone density Risk of thinning bones

Many transplant centres run long-term follow-up clinics, so that late effects are checked for and managed for life.

9. Alternatives

Alternative When it is considered
Chemotherapy-only conditioning Very young children, people with previous radiotherapy, many myeloid conditions
Allogeneic stem cell transplant with reduced-intensity chemotherapy Older or less fit patients
CAR-T cell therapy Some relapsed B-cell ALL, sometimes instead of or before transplant
Autologous stem cell transplant Uses your own stem cells; TBI is rarely part of this today

10. Frequently asked questions

Question Answer
Will I be radioactive? No, external radiotherapy does not make you radioactive
Does it hurt? The radiation is painless; staying still can be uncomfortable
Will my hair grow back? Usually, within a few months
Will I be able to have children? High-dose TBI usually causes infertility; discuss fertility preservation first
Can TBI be repeated? Generally not, because of the total dose to organs
Why not just use chemotherapy? For some leukaemias, TBI gives better results, but this depends on age and diagnosis
Can I have visitors during TBI? Usually yes, with infection precautions on the transplant unit
Will TBI affect my thinking? Adults rarely notice lasting effects; young children are monitored for learning difficulties
Will I need a wheelchair or special position? Some centres use a support stand or couch; the team will show you beforehand
How long until I feel normal? Often 6-12 months after transplant

11. Questions to ask your care team

  • Why is TBI recommended for me rather than chemotherapy alone?
  • Is this high-dose or low-dose TBI?
  • What are the late effects I should watch for?
  • What are my fertility options?
  • How will my lungs and other organs be protected?
  • What long-term follow-up will I need?

Resources

  1. Gupta, T. et al. (2011) ‘Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis’, Hematology/Oncology and Stem Cell Therapy, 4(1), pp. 17-29.
  2. McSweeney, P.A. et al. (2001) ‘Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects’, Blood, 97(11), pp. 3390-3400.
  3. Peters, C. et al. (2021) ‘Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study’, Journal of Clinical Oncology, 39(4), pp. 295-307.
  4. Wong, J.Y.C. et al. (2018) ‘Total body irradiation: guidelines from the International Lymphoma Radiation Oncology Group (ILROG)’, International Journal of Radiation Oncology, Biology, Physics, 101(3), pp. 521-529.
  5. National Cancer Institute (2026) Stem Cell and Bone Marrow Transplants for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant (Accessed: October 2026).
  6. National Cancer Institute (2026) Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.